WO2009154396A3 - Préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée - Google Patents

Préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée Download PDF

Info

Publication number
WO2009154396A3
WO2009154396A3 PCT/KR2009/003228 KR2009003228W WO2009154396A3 WO 2009154396 A3 WO2009154396 A3 WO 2009154396A3 KR 2009003228 W KR2009003228 W KR 2009003228W WO 2009154396 A3 WO2009154396 A3 WO 2009154396A3
Authority
WO
WIPO (PCT)
Prior art keywords
crude drug
sustained releasing
controlled release
drug extract
releasing preparation
Prior art date
Application number
PCT/KR2009/003228
Other languages
English (en)
Other versions
WO2009154396A2 (fr
Inventor
Hee-Joo Kil
Jung-Sik Lee
Je-Kyo Jeong
Gyo-Cheol Gu
Seon-Hwa Jung
Ji-Eun Kim
Original Assignee
Pharmapex Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090053084A external-priority patent/KR20090131256A/ko
Application filed by Pharmapex Co., Ltd. filed Critical Pharmapex Co., Ltd.
Priority to CN2009800004796A priority Critical patent/CN101896168A/zh
Publication of WO2009154396A2 publication Critical patent/WO2009154396A2/fr
Publication of WO2009154396A3 publication Critical patent/WO2009154396A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Plant Substances (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne une préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée, et en particulier une préparation à libération prolongée renfermant un extrait de médicament brut de Salvia miltiorrhiza Bunge, Panax notoginseng Burk, borneolum, etc., ainsi qu’une macromolécule insoluble dans l’eau et/ou un vecteur à libération prolongée présentant un effet de libération régulière de médicament sur 24 heures, et pouvant permettre d’atteindre rapidement la région thérapeutique initiale ainsi que de maintenir la concentration du médicament à l’intérieur de ladite région thérapeutique durant 24 heures dans le sang.
PCT/KR2009/003228 2008-06-17 2009-06-16 Préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée WO2009154396A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009800004796A CN101896168A (zh) 2008-06-17 2009-06-16 用于阻止水分增加并控制释放的包含生药提取物的缓释制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0056664 2008-06-17
KR20080056664 2008-06-17
KR1020090053084A KR20090131256A (ko) 2008-06-17 2009-06-15 함습 억제 및 방출속도 조절을 위한 생약추출물 함유 서방성 제제
KR10-2009-0053084 2009-06-15

Publications (2)

Publication Number Publication Date
WO2009154396A2 WO2009154396A2 (fr) 2009-12-23
WO2009154396A3 true WO2009154396A3 (fr) 2010-03-25

Family

ID=41434552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003228 WO2009154396A2 (fr) 2008-06-17 2009-06-16 Préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée

Country Status (1)

Country Link
WO (1) WO2009154396A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044902A (zh) * 2018-08-17 2018-12-21 王凡 一种灯盏花乙素牙膏及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1396920B1 (it) * 2009-11-11 2012-12-20 Velleja Res Srl Formulazioni comprendenti acido carnosico, o derivati estrattivi che lo contengano, per il trattamento e la prevenzione dell'ipertrigliceridemia
WO2011143844A1 (fr) * 2010-05-21 2011-11-24 深圳市齐旺投资有限公司 Composition de médecine chinoise traditionnelle pour traiter l'infection du sous-type de virus de la grippe a et procédé de préparation de celle-ci
CN102657719A (zh) * 2012-04-27 2012-09-12 中国人民解放军第三七一医院 一种治疗高血脂的中药制剂
CN109602653B (zh) * 2018-12-17 2022-01-11 广州市白云区研美化妆品厂 具有美白功效的组合物、化妆品、精华液及其制备方法
CN112120970B (zh) * 2020-09-29 2023-02-03 上海相宜本草化妆品股份有限公司 一种具有促渗作用的中草药精油组合物、其制备方法及用途
CN114470508B (zh) * 2022-01-26 2023-07-21 中原工学院 一种具有药物缓释作用的理疗盐枕材料、制备方法和应用
CN115501156B (zh) * 2022-09-28 2023-12-29 福建片仔癀化妆品有限公司 一种具有美白舒缓功效的化妆品原料组合物及其评价体系

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980066045A (ko) * 1997-01-18 1998-10-15 이영호 부형제가 함유되지 않은 생약의 순수엑스건조분말 및 그의 제조방법
US20030068369A1 (en) * 2001-01-30 2003-04-10 Mcallister Stephen Mark Pharmaceutical formulation
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980066045A (ko) * 1997-01-18 1998-10-15 이영호 부형제가 함유되지 않은 생약의 순수엑스건조분말 및 그의 제조방법
US20030068369A1 (en) * 2001-01-30 2003-04-10 Mcallister Stephen Mark Pharmaceutical formulation
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044902A (zh) * 2018-08-17 2018-12-21 王凡 一种灯盏花乙素牙膏及其应用

Also Published As

Publication number Publication date
WO2009154396A2 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
WO2009154396A3 (fr) Préparation à libération prolongée renfermant un extrait de médicament brut servant à prévenir l’humidification et permettant une libération prolongée
WO2011018501A3 (fr) Composition comprenant une fraction non saponifiable
WO2009148620A3 (fr) Anthraquinones et analogues provenant de rheum palmatum pour le traitement d'états à médiation par le récepteur bêta de l'œstrogène
EP2278985A4 (fr) Extraits de plantes médicinales utilisant un traitement de plante médicinale et composition pour application externe sur la peau comprenant ceux-ci
WO2010062581A3 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
WO2009034559A3 (fr) Procédé cosmétique pour un traitement esthétique et/ou de réparation de la peau
EP2273999A4 (fr) Composition comprenant un polysaccharide extrait de panax ginseng destinée à la prévention et au traitement de maladies hépatiques
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2010067286A3 (fr) Vaccin peptidique ige ch3
WO2007131677A8 (fr) Utilisation de ginsénosides et d'extraits qui les contiennent
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
WO2009106975A3 (fr) Activation de réponses immunitaires innées et adaptatives par un extrait de ginseng
WO2008127302A3 (fr) Compositions utilisées pour traiter et inhiber la douleur
WO2011063178A3 (fr) Infusion intraveineuse de curcumine et de bloqueur des canaux calciques
WO2011051633A3 (fr) Utilisation d'un extrait de punica granatum pour lutter contre la canitie
HK1137661A1 (en) A chinese medicine composition and the extract of worms thereof and their preparation
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
EP2083838A4 (fr) Extrait de plante médicinale exercant un effet contre l'obésité
WO2008062467A3 (fr) Mélanocytes cultivés sur biopolymères
WO2010019864A3 (fr) Extraits de ficus ayant une activité d'inhibition d'angiogenèse, et procédés d'isolation et d'utilisation de ceux-ci
WO2007083006A3 (fr) Utilisation d'un extrait insaponifiable de pulpe vegetale dans le traitement du vieillissement cutane
WO2011024168A3 (fr) Systèmes de délivrance à libération prolongée pour la prévention et le traitement de cancers de la tête et du cou
SG169346A1 (en) Use of yeast flakes for treating and/or preventing hyperinsulinemia
WO2007113531A3 (fr) Administration de médicament topique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000479.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09766821

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09766821

Country of ref document: EP

Kind code of ref document: A2